Translational Regenerative Medicine: Market Prospects 2015-2025

トランスレーショナル再生医療の世界市場:幹細胞治療、ティッシュ・エンジニアリング治療、遺伝子治療

◆タイトル:Translational Regenerative Medicine: Market Prospects 2015-2025
◆商品コード:VGAIN5020411
◆調査・発行会社:visiongain
◆発行日:2015年2月
◆ページ数:260
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:世界
◆産業分野:医療
◆販売価格オプション(消費税別)
Single UserGBP1,799 ⇒換算¥269,850見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥449,850見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥749,850見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、トランスレーショナル再生医療の世界市場について調査・分析し、以下の構成でお届けいたします。

・レポートの概要
・イントロダクション
・トランスレーショナル再生医療の世界市場
 (市場規模予測、市場の成長要因・阻害要因など)
・幹細胞治療市場
・ティッシュ・エンジニアリング治療市場
・遺伝子治療市場
・地域別市場分析
・主要企業分析
・結論

Translational Regenerative Medicine – new study showing you trends, R&D progress, and predicted revenues
Where is the market for regenerative medicine heading? What are the commercial prospects for this market and related technologies? Visiongain’s brand new report shows you potential revenues and other trends to 2025, discussing data, opportunities and prospects.

Visiongain’s report lets you assess regenerative medicine: cell-based therapies that aim to restore function and regenerate diseased tissues. Our 260 page report provides 145 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at world market, submarket and national level. You will see financial results, interviews, trends, opportunities and revenue predictions.

Forecasts from 2015-2025 and other analyses show you commercial prospects
Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. There you will find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter’s Five Forces), company profiles and commercial developments. Read the full transcript of an exclusive expert opinion interview from industry specialists informing your understanding and allowing you to assess prospects for investments and sales:
• Dr Antonio SJ Lee, CEO and Managing Director, MEDIPOST America Inc.

You find prospects for key submarkets and products
In addition to analyses of the overall world market, you see revenue forecasts for these three submarkets to 2025:
• Stem cell therapies
• Gene Therapies
• Tissue engineering products

Products that can significantly increase disease-free survival and improve patient tolerance will achieve success. In the long term, we forecast these curative therapies to be adopted by many healthcare systems globally.

Our investigation shows business research and analyses with individual revenue forecasts and discussions. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.

See revenue forecasts for products
How will leading products perform to 2025 at the world level? Our study forecasts sales of currently marketed and pipeline regenerative medicine products including these:
• Osteocel Plus
• Trinity ELITE and Trinity Evolution
• Prochymal
• Apligraf
• Dermagraft
• ReCell
• Neovasculgen
• Glybera
• Talimogene Laherparepvec (T-Vec)

Discover how high revenues can go. You will see what is happening, understanding trends, challenges and opportunities.

What are the prospects for the leading regions and countries?
In addition to analyses of the overall world market, you discover individual revenue forecasts for regional markets to 2025, with discussions of countries. There are many commercial opportunities in developed and developing countries.
• US
• Europe
• Asia Pacific – including China, Japan, India, South Korea and Australia
• Rest of the world – including Brazil

Our analyses show sustained growth in the translational regenerative medicine market, particularly in Asia-Pacific where less regulatory pressures will catalyse successful market entry.

Leading companies and potential for market growth
This decade, this biotechnology sector will flourish – already there are products on sale and a myriad of clinical trials underway.

The R&D pipeline is strong and promising. Visiongain expects high demand for treatments, with degenerative diseases, wound healing, and other applications stimulating progress.

Our work shows you what products and organisations hold greatest potential. See profiles of 17 leading companies, including these:
• Alphatec Spine
• Anterogen
• Avita Medical
• Medipost
• Mesoblast
• NuVasive
• Organogenesis
• Osiris Therapeutics
• Regenerys
• TiGenix
• UniQure

【レポートの目次】

1. Report Overview
1.1 Global Translational Regenerative Medicine: Market Overview
1.2 Global Translational Regenerative Medicine Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered By This Analytical Report
1.6 Who Is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain

2. An Introduction To Translational Regenerative Medicine
2.1 What is Regenerative Medicine?
2.1.1 Translational Regenerative Medicine – From Bench To Bedside
2.2 Translational Regenerative Medicine – Market Breakdown
2.2.1 Stem Cell Therapy – Marketable Differentiation And Specialisation
2.2.1.1 How Embryonic Stem Cells (ESCs) Entered The Fray
2.2.1.2 Classifying Stem Cells by Potency
2.2.1.3 Stem Cells Categories: ESCs, SSCs, iPSCs
2.2.1.4 Parthenogenetic Stem Cells: Ethical ESC-Like Cells?
2.2.1.5 Autologous versus Allogeneic Stem Cells: Towards Universal Stem Cell Products?
2.2.2 Tissue Engineering – Invitro Manipulation For Therapeutic Purposes
2.2.3 Gene Therapies
2.2.3.1 Harnessing Infectivity: Viral Vectors in Gene Therapy
2.3 Other Approaches To Regenerative Medicine
2.3.1 Small Molecules and Proteins – Scaffold-Based Delivery Of Signalling Molecules
2.3.2 Cosmetic Applications of Regenerative Medicine
2.4 Regulation of Regenerative Medicine
2.4.1 Regulation of Regenerative Medicine Products in Europe
2.4.2 Regulation of Regenerative Medicine Products in the US
2.5 The Phases of Clinical Trials
2.6 Market Definition
2.6.1 Products Excluded From The Report

3. Translational Regenerative Medicine Market, 2015-2025
3.1 Global Translational Regenerative Medicine: Market Overview
3.1.1 Segments Within The Global Translational Regenerative Medicine Market
3.2 The Global Translational Regenerative Medicine Market In 2013 And 2014
3.3 Global Translational Regenerative Medicine: Market Forecast 2015-2025
3.3.1 Market Sectors That Will Drive Regenerative Medicine Growth
3.3.2 Global Translational Regenerative Medicine Market – Changing Market Shares By Sector 2015-2025

4. Stem Cell Therapies: Leading Applications, 2015-2025
4.1 The Global Market For Stem Cell Therapies, 2013 And 2014
4.1.1 Stem Cell Therapies: Currently Available Therapies
4.1.2 Haematopoietic Stem Cell Transplantation (HSCT)
4.1.3 Stem Cell Orthobiologics
4.2 Stem Cell Therapies: Global Market Forecast 2015-2025
4.3 AlloStem (AlloSource)
4.4 Osteocel Plus (NuVasive)
4.4.1 Osteocel Plus: Sales Forecast 2015-2025
4.5 Trinity ELITE and Trinity Evolution (Orthofix)
4.5.1 Trinity ELITE and Trinity Evolution: Sales Forecast, 2015-2025
4.6 PureGen (AlphaTec Spine)
4.7 Other Approved Stem Cell Therapy Products, 2015
4.7.1 Cartistem (Medipost)
4.7.2 Cupistem (Anterogen)
4.7.3 Hearticellgram-AMI (Pharmicell)
4.7.4 Prochymal/ Remestemcel-L (Mesoblast)
4.7.4.1 Prochymal/ Remestemcel-L: Sales Forecast 2015-2025
4.8 Development Pipeline For Stem Cell Therapies, 2015-2025
4.8.1 Late-Stage Pipeline for Stem Cell Therapies, 2015
4.8.1.1 StemEx (Gamida Cell)
4.8.1.2 Mesenchymal Precursor Cell Therapies (Mesoblast)
4.8.1.3 Adult Autologous CD34+ Cells (Baxter)
4.8.1.4 MyoCell (Bioheart)
4.8.1.5 Cx601 (TiGenix)
4.8.1.6 Adipose-Derived Stem Cells (Cytori Therapeutics)
4.8.1.7 Stempeucel (Stempeutics Research)
4.8.1.8 C-Cure (Cardio3 BioSciences)
4.8.1.9 Other Late-Stage Stem Cell Therapies
4.8.2 Diabetes And Stem Cell Therapy
4.8.2.1 Mesenchymal Precursor Cells (Mesoblast)
4.8.2.2 VC-01 (ViaCyte Inc)
4.8.2.2.1 Clinical Development Efforts For VC-01 For The Treatment Of Diabetes
4.8.3 Cardiovascular Disease And Stem Cell Therapy
4.8.3.1 Endometrial Regenerative Cells (MediStem, Intrexon)
4.8.3.2 AMR-001 (NeoStem)
4.8.3.3 CAP-1002 (Capricor)
4.8.4 Stem Cell Therapy in Cancer
4.8.4.1 CLT-008 (Cellerant Therapeutics)
4.8.4.2 OncoCyte/BioTime – Targeting Cancer With Gene And Stem Cell Therapy
4.8.5 Stem Cell Therapy For Central Nervous System (CNS) Conditions
4.8.5.1 NurOwn (BrainStorm Cell Therapeutics)
4.8.5.1.1 Clinical Development Efforts for NorOwn, 2015
4.8.5.2 NSI-566 (Neuralstem)
4.8.5.3 MultiStem (Athersys)
4.8.5.4 PDA-001 (Cenplacel-L, Celgene)
4.8.5.5 ALD-401 (Cytomedix)
4.8.5.6 ReN001 (ReNeuron)
4.8.6 Stem Cell Therapy for Eye Diseases
4.8.6.1 MA09-hRPE (Advanced Cell Technology)
4.8.6.2 HuCNS-SC (StemCells Inc.)
4.8.6.3 Collaboration And License Agreement Between Pfizer And The London Project to Cure Blindness
4.9 Stem Cells Therapy Market: Drivers and Restraints 2015-2025

5. Tissue Engineering Therapies: Leading Applications, 2015-2025
5.1 The Global Market For Tissue Engineered Therapies, 2013 And 2014
5.1.1 Tissue Engineering Therapies: Currently Available Therapies
5.2 Tissue Engineering Therapies: Global Market Forecast 2015-2025
5.3 Tissue Engineering In Wound Repair And Healing
5.3.1 Apligraf (Organogenesis)
5.3.1.1 Apligraf: Historical Sales Analysis
5.3.1.2 Apligraf: Sales Forecast 2015-2025
5.3.2 BioDfence and BioDfactor (BioD)
5.3.3 CureXcell (MacroCure)
5.3.4 Dermagraft (Organogenesis)
5.3.4.1 Dermagraft (Shire): Sales Forecast 2015-2025
5.3.5 Epicel (Aastrom)
5.3.6 Grafix (Osiris Therapeutics)
5.3.7 MySkin and CyroSkin (Regenerys)
5.3.8 ReCell (Avita Medical)
5.3.8.1 ReCell (Avita Medical): Sales Forecast 2015-2025
5.4 Tissue Engineering for Cartilage Repair
5.4.1 Autologous Chondrocyte Implantation (ACI)
5.4.2 Carticel (Aastrom Biosciences)
5.4.3 ChondroCelect (TiGenix, Sobi Partners)
5.4.4 DeNovo NT (Zimmer)
5.4.5 MACI (Aastrom Biosciences)
5.5 Other Available Tissue Engineering Therapies
5.5.1 Autologous Cultured Cell and Tissue Products (Japan Tissue Engineering Co.)
5.5.2 Gintuit (Organogenesis)
5.5.3 LAVIV (azficel-T), (Fibrocell Science)
5.5.4 Acellular Tissue Engineering Products
5.6 Tissue Engineering: Development Pipeline, 2015-2025
5.6.1 Pipeline Products For Autologous Chondrocyte Implantation
5.6.2 Tissue Engineering For Skin
5.6.3 Tissue Engineering for Liver Diseases
5.6.3.1 Extracorporeal Bio-Artificial Liver Therapy (Vital Therapies)
5.6.4 Tissue Engineering for Cardiovascular Disease
5.6.5 Tissue Engineering for Eye Diseases
5.7 Future Prospects for Organ Transplantation and Tissue Engineering
5.8 Tissue Engineered Products Market: Drivers and Restraints 2015-2025

6. Gene Therapies: Leading Applications, 2015-2025
6.1 The Global Market For Gene Therapies, 2013 And 2014
6.2 Gene Therapies: Global Market Forecast 2015-2025
6.3 Currently Available Gene Therapy Products
6.3.1 Gendicine (Benda Pharmaceutical)
6.3.2 Oncorine (Shanghai Sunway Biotech)
6.3.3 Neovasculgen (Human Stem Cells Institute)
6.3.3.1 Neovasculgen (HSCI): Sales Forecast 2015-2025
6.3.4 Glybera (UniQure)
6.3.4.1 Glybera: Sales Forecast 2015-2025
6.4 Development Pipeline For Gene Therapies, 2015-2025
6.4.1 Late-Stage Pipeline Gene Therapies, 2015
6.4.1.1 Collategene (beperminogene perplasmid) – (AnGes MG/Vical)
6.4.1.2 ProstAtak (AdV-tk) – (Advantagene)
6.4.1.3 Trinam (taberminogene vadenovec) – (Ark Therapeutics)
6.4.1.4 T-VEC (talimogene laherparepvec) – (Amgen)
6.4.1.4.1 Clinical Trials And Development Efforts For T-Vec
6.4.1.4.2 Talimogene Laherparepvec (T-Vec) – Sales Forecast 2015-2025
6.4.1.5 AAV2-hRPE65v2 (Spark Therapeutics)
6.4.1.6 CG0070 (Cold Genesys)
6.4.2 Gene Therapy For Use In The Treatment Of Diabetes
6.4.3 Gene Therapy Directed At Oncology Indications
6.4.4 Gene Therapy Directed At Neurological Diseases
6.4.5 Gene Therapy Directed At Tackling Haemophilia B
6.5 Gene Therapy Market: Drivers and Restraints 2015-2025

7. Leading National Markets for Translational Regenerative Medicine, 2015-2025
7.1 The Translational Regenerative Medicine Market By Region
7.1.1 The Global Distribution of Translational Regenerative Medicine In 2013 And 2014
7.2 Leading National Markets: Forecast 2015-2025
7.2.1 Changing Market Shares By Region, 2015-2025
7.3 Regional Translational Regenerative Medicine Markets: Analysis And Forecasts, 2015-2025
7.4 United States: The Largest Translational Regenerative Medicine Market
7.4.1 US Translational Regenerative Medicine Market: Market Drivers And Restraints, 2015-2025
7.4.2 US Translational Regenerative Medicine Market: Market Forecast 2015-2025
7.4.3 The Regulatory Framework For Regenerative Medicine In The US
7.4.4 The Impact Of Ethical And Regulatory Reluctance To Embryonic Stem Cell Research And Its Impact On Funding
7.4.5 How Is The Ending Of Patenting For Human Gene Products Affecting The Regenerative Medicine Market In The US?
7.5 Europe: A Fragmented Regenerative Medicine Market
7.5.1 European Regenerative Medicine Market: Market Drivers and Restraints, 2015-2025
7.5.2 European Regenerative Medicine Market: Market Forecast 2015-2025
7.5.3 Europe’s Unitary Patent System And Its Impact On The Future Of Regenerative Medicine In The Region
7.5.4 Regulation Of Regenerative Medicine In The European Union
7.5.5 UK: A Leading Research Centre For Regenerative Medicine In Europe
7.5.5.1 Regulation of Stem Cell Research In The UK
7.5.6 Russia: Rising Interest In Regenerative Medicine Research
7.6 Asia-Pacific: Accommodating Regulatory Landscape Aiding Rapid Product Commercialisation
7.6.1 Asia-Pacific Regenerative Medicine Market: Market Drivers and Restraints, 2015-2025
7.6.2 Asia-Pacific Regenerative Medicine Market: Market Forecast 2015-2025
7.6.3 Australia: Encouraging Translational Regenerative Medicine
7.6.4 China: Encouraging Stem Cell R&D
7.6.4.1 Government Intervention Into RM Research In China
7.6.4.2 Regulation Of Stem Cell Research In China
7.6.4.3 Commercialisation Of Gene Therapy And Tissue Engineering Products In China
7.6.4.4 Medical Tourism Impacting Market Growth For Regenerative Medicine In China
7.6.5 Japan: Difficulty In Translating Research Into Commercialisation
7.6.5.1 Research Funding: A Major Determinant Of Growth In Japan’s Regenerative Medicine
7.6.5.2 Government Interventions In Promoting Stem Cell Research In Japan
7.6.5.3 Regulation of Regenerative Medicine In Japan
7.6.6 India: An Emerging Market For Regenerative Medicine
7.6.6.1 Efforts In Stem Cell Research In India
7.6.6.2 Unclear Guidelines Hindering Progression Of Gene Therapy Research In India
7.6.7 South Korea: First to Approve Stem Cell Treatments
7.6.7.1 A Regeneration In South Korea’s Stem Cell Research Efforts
7.7 Rest of the World: Regenerative Medicine Conquering New Territories And Booming
7.7.1 Rest of the World Regenerative Medicine Market: Market Forecast 2015-2025

8. Leading Companies In The Translational Regenerative Medicine Market, 2015-2025
8.1 Translational Regenerative Medicine: A Hotbed For Innovation
8.2 Aastrom Biosciences
8.2.1 Aastrom’s Acquisition Of Sanofi’s Regenerative Medicine Business
8.2.2 Aastrom: Historical Financial And Performance Analysis, 2011-2013
8.2.3 Aastrom Regenerative Medicine Portfolio, 2015
8.2.4 Aastrom: Pipeline Analysis, 2015
8.3 Alphatec Spine
8.3.1 Alphatec Spine: Financial And Performance Analysis, 2009-2013
8.3.2 Alphatec Spine’s Shifting Focus From Regenerative Medicine To Medical Devices
8.4 Anterogen
8.4.1 Anterogen: Pipeline Analysis, 2015
8.5 Athersys
8.5.1 Athersys: Financial And Performance Analysis, 2010-2013
8.5.2 Athersys: Pipeline Analysis, 2015
8.5.2.1 MultiStem Technology – Potential Treatment For A Range Of Diseases
8.6 Avita Medical
8.6.1 Avita Medical: Historical Financial And Performance Analysis, 2013-2014
8.6.2 Avita Medical: Regenerative Medicine Portfolio, 2015
8.6.3 Avita Medical: Pipeline Analysis, 2015
8.7 AxoGen
8.7.1 AxoGen: Historical Financial And Performance Analysis, 2010-2013
8.7.2 AxoGen: Regenerative Medicine Portfolio, 2015
8.7.3 AxoGen: Pipeline Analysis, 2015
8.8 Medipost
8.8.1 Medipost: Historical Financial And Performance Analysis, 2011-2013
8.8.2 Medipost: Regenerative Medicine Portfolio, 2015
8.8.3 Medipost: Pipeline Analysis, 2015
8.9 Mesoblast
8.9.1 Mesoblast Product Portfolio, 2015
8.9.2 Mesoblast: Historical Financial And Performance Analysis, 2011-2014
8.9.3 Mesoblast: Pipeline Analysis, 2015
8.9.3.1 NeoFuse
8.9.3.2 Chondrogen
8.9.3.3 Prochymal
8.9.3.4 Other Recent Pipeline Acquisitions By Mesoblast
8.10 NuVasive
8.10.1 NuVasive Product Portfolio, 2015
8.10.2 NuVasive: Historical Financial And Performance Analysis, 2009-2013
8.10.3 NuVasive: Pipeline Analysis, 2015
8.11 Ocata Therapeutics
8.11.1 Ocata Therapeutics: Historical Financial And Performance Analysis, 2009-2013
8.11.2 Ocata Therapeutics: Pipeline Analysis, 2015
8.11.2.1 Retinal Pigment Epithelial Cell Therapy
8.11.2.2 Research Around iPSC-derived Platelets
8.11.2.3 Hemangioblast As A Treatment for Blood And Cardiovascular Diseases
8.11.2.4 Mesenchymal Stem Cell Program – Tissue Repair Functionalities
8.11.3 Ocata’s Other Therapeutic Platforms
8.12 Organogenesis
8.12.1 Organogenesis RM Portfolio, 2015
8.12.2 Organogenesis: Pipeline Analysis, 2015
8.13 Osiris Therapeutics
8.13.1 Osiris Therapeutics: RM Portfolio, 2015
8.13.2 Osiris Therapeutics: Historical Financial And Performance Analysis, 2010-2013
8.13.3 Osiris Therapeutics: Pipeline Analysis, 2015
8.14 Pharmicell
8.14.1 Pharmicell: Historical Financial And Performance Analysis, 2011-2013
8.14.2 Pharmicell: Pipeline Analysis, 2015
8.15 Regenerys
8.15.1 Regenerys: RM Portfolio, 2015
8.15.2 Regenerys: Pipeline Analysis, 2015
8.16 Shire
8.16.1 Shire: RM Portfolio, 2015
8.16.2 Shire: Historical Financial And Performance Analysis, 2010-2013
8.16.3 Shire: Pipeline Analysis, 2015
8.16.3.1 Vascugel
8.17 TiGenix
8.17.1 TiGenix: Historical Financial And Performance Analysis, 2011-2013
8.17.2 TiGenix: Pipeline Analysis, 2015
8.18 UniQure
8.18.1 UniQure: Pipeline Analysis, 2015

9. Qualitative Analysis for the Global Translational Regenerative Medicine Market, 2015-2025
9.1 Market Factors Influencing The Translational Regenerative Medicine Market
9.2 SWOT Analysis Of The Translation Market, 2015-2025
9.2.1 Strengths
9.2.1.1 Improvements In Regulatory Frameworks
9.2.1.2 Advancements In General Cellular And Tissue Research Aiding Regenerative Medicine
9.2.1.3 Strong Support From Governments In Multiple Regions
9.2.1.4 Increasing Ease Of Product Commercialisation And Market Access
9.2.2 Weaknesses
9.2.2.1 The High Price Of Regenerative Medicine Products May Restrain Market Growth
9.2.2.2 Lack Of Funding From Venture Capital
9.2.2.3 The Intrinsic Lack Of Standardisation Is A Burden To Scaling Up Manufacturing
9.2.2.4 Successful Commercialisation Of RM Products Requires New Business Models
9.2.3 Opportunities
9.2.3.1 3D Bioprinting And Other Technologies May Enable Rapid Scale-Up
9.2.3.2 Medical Tourism May Stimulate Standardisation And Drive Market Growth
9.2.3.3 Disruptive Regenerative Medicine Therapies Can Create New Markets
9.2.4 Threats
9.2.4.1 Ethical Concerns Limiting R&D In Regenerative Medicine
9.2.4.2 Difficulty Establishing An Evidence Base For Long-Term Efficacy Of RM Therapies
9.2.4.3 Rate Of Scientific Progress – A Major Determinant Of RM Market Growth
9.2.4.4 Restraints On Reimbursement May Slow Growth
9.3 Porter’s Five Force Analysis Of The Translational Regenerative Medicine Market, 2015-2025
9.3.1 Threat Of New Entrants
9.3.2 Threat Of Substitutes
9.3.3 Power Of Suppliers
9.3.4 Power Of Buyers
9.3.5 Rivalry Among Competitors

10. Expert Opinions from Our Primary Research
10.1 Interview With Antonio S J Lee Ph.D, CEO & Managing Director For MEDIPOST America Inc.
10.1.1 MEDIPOST And Recent Developments In Regenerative Medicine
10.1.2 The Transition From Mid- To Late-Stage Clinical Trials In The RM Market And Its Likely Implications
10.1.3 CARTISTEM®, PNEUMOSTEM®, NEUROSTEM® – Medipost’s Development Plans In Regenerative Medicine
10.1.4 Cord Blood Banking And Korea’s Role In Its Advancement
10.1.5 The Role Of R&D Strategies And Long-Term Efficacy Data In The Future Success Of Regenerative Medicine
10.1.6 The Role Of Big-Pharma Companies In Regenerative Medicine And The Need For Regulatory Harmonisation
10.1.7 On The Unmet Needs For Regenerative Medicine To Target
10.1.8 On The Future Developments To Expect In The Market For Regenerative Medicine Over The Next Decade

11. Conclusions
11.1 Overview Of Current Market Conditions And Market Forecast, 2013-2025
11.2 Leading Regenerative Medicine Segments In 2013
11.3 Leading Regions In The Translational Regenerative Medicine Market In 2013 And 2014
11.4 Future Outlook For The Various Sectors Within TRM, 2015-2025
11.5 R&D Pipeline Products Crucial To Future Market Growth
11.6 What Does The Future Hold For Regenerative Medicine?

List of Tables
Table 1.1 Global Translational Regenerative Medicine Market: Market Forecast ($m, AGR%, CAGR%) by Region, 2013-2025 (Altered Data)
Table 2.1 European Union Definitions of Regenerative Medicine Products, 2015
Table 2.2 Potency and Source of Stem Cells, 2015
Table 2.3 Germ Layers and Their Associated Types of Cells and Organs, 2015
Table 2.4 Major Types Of Stem Cells and Their Properties, 2015
Table 2.5 Terminology For Stem Cell Donor-Types, 2015
Table 2.6 Clinical Trial Phases, 2015
Table 3.1 The Global Translational Regenerative Medicine Market: Revenue ($m) and Market Shares (%) by Sector, 2013 and 2014
Table 3.2 The Global Translational Regenerative Medicine Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2013-2025
Table 3.3 The Global Translational Regenerative Medicine Market Forecast: CAGR (%) by Sector, 2013-2019, 2019-2025, 2013-2025
Table 3.4 The Global Translational Regenerative Medicine Market: Revenue ($m) by Sector, 2013, 2019, 2025
Table 3.5 The Global Translational Regenerative Medicine Market: Market Share (%) by Sector, 2013, 2018, 2025
Table 4.1 Selected Stem Cell Products Currently Available On The Market, 2015
Table 4.2 Stages of Osteogenesis, 2015
Table 4.3 Global Stem Cell Therapies: Market Forecast ($m, AGR%, CAGR%), 2013-2025
Table 4.4 Osteocel Plus: Sales Forecast ($m, AGR%, CAGR%), 2013-2025
Table 4.5 Trinity ELITE: Sales Forecast ($m, AGR%, CAGR%), 2013-2025
Table 4.6 Prochymal: Sales Forecast ($m, AGR%, CAGR%), 2013-2025
Table 4.7 Stem Cell Therapy Pipeline: Therapies in Late-Stage Clinical Trials, 2015
Table 4.8 Stem Cell Therapies: Drivers and Restraints, 2015-2025
Table 5.1 Selected Tissue Engineering Products Currently Available On The Market, 2015
Table 5.2 Global Tissue Engineering Therapies: Market Forecast ($m, AGR%, CAGR%), 2013-2025
Table 5.3 Apligraf: Sales Forecast ($m, AGR%, CAGR%), 2013-2025
Table 5.4 Dermagraft: Sales Forecast ($m, AGR%, CAGR%), 2013-2025
Table 5.5 ReCell: Sales Forecast ($m, AGR%, CAGR%), 2013-2025
Table 5.6 Vital Therapies: Extracorporeal Bio-Artificial Liver Therapy Clinical Trials, 2015
Table 5.7 Tissue Engineered Therapy Products: Drivers and Restraints, 2015-2025
Table 6.1 Currently Available Gene Therapy Products, 2015
Table 6.2 Global Gene Therapies: Market Forecast ($m, AGR%, CAGR%), 2013-2025
Table 6.3 Neovasculgen: Sales Forecast ($m, AGR%, CAGR%), 2013-2025
Table 6.4 Glybera: Sales Forecast ($m, AGR%, CAGR%), 2013-2025
Table 6.5 Gene Therapy Pipeline: Therapies in Late-Stage Clinical Trials, 2015
Table 6.6 Advantegene: Gene Therapy Clinical Trials, 2015
Table 6.7 Amgen: Gene Therapy Clinical Trials, 2015
Table 6.8 Talimogene Laherparepvec (T-Vec) Sales Forecast ($m, AGR%, CAGR%), 2013-2025
Table 6.9 Spark Therapeutics: Gene Therapy Clinical Trials, 2015
Table 6.10 Recent Developments In Gene Therapy For Use In Diabetes
Table 6.11 Gene Therapy Products In The Development Pipeline For Neurological Diseases, 2015
Table 6.12 Gene Therapy Products: Market Drivers and Restraints, 2015-2025
Table 7.1 The Global Translational Regenerative Medicine Market: Market Size ($m) and Market Share (%) by Region, 2013 and 2014
Table 7.2 Global Translational Regenerative Medicine Market: Market Forecast ($m, AGR%, CAGR%) by Region, 2013-2025
Table 7.3 Global Translational Regenerative Medicine Market: CAGR (%) by Region, 2013-2019, 2019-2025, 2013-2025
Table 7.4 Global Translational Regenerative Medicine Market: Market Share (%) by Region, 2013, 2019, 2025
Table 7.5 US Translational Regenerative Medicine Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2013-2025
Table 7.6 US Translational Regenerative Medicine: Market Drivers and Restraints, 2015-2025
Table 7.7 US Translational Regenerative Medicine Market: Market Forecast ($m, AGR%, CAGR%), 2013-2025
Table 7.8 European Translational Regenerative Medicine Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2013-2025
Table 7.9 European Translational Regenerative Medicine: Market Drivers and Restraints, 2015-2025
Table 7.10 European Translational Regenerative Medicine Market: Market Forecast ($m, AGR%, CAGR%), 2013-2025
Table 7.11 Asia-Pacific Translational Regenerative Medicine Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2013-2025
Table 7.12 Asia-Pacific Translational Regenerative Medicine: Market Drivers and Restraints, 2015-2025
Table 7.13 Asia-Pacific Translational Regenerative Medicine Market: Market Forecast ($m, AGR%, CAGR%), 2013-2025
Table 7.14 Rest of the World Translational Regenerative Medicine Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2013-2025
Table 7.15 Rest of the World Translational Regenerative Medicine Market: Market Forecast ($m, AGR%, CAGR%), 2013-2025
Table 8.1 Aastrom: Historical Sales ($Thousand, AGR%), 2011-2013
Table 8.2 Aastrom Biosciences: Regenerative Medicine Clinical Trials, 2015
Table 8.3 Alphatec Spine: Historical Sales ($m) and Operating Loss ($m), 2009-2013
Table 8.4 Alphatec Spine: Regenerative Medicine Clinical Trials, 2015
Table 8.5 Anterogen: Regenerative Medicine Clinical Trials, 2015
Table 8.6 Athersys: Historical Sales ($m) 2010-2013
Table 8.7 Athersys: Regenerative Medicine Clinical Trials, 2015
Table 8.8 Avita Medical: Historical Sales ($m, AUD m) and Net Loss ($m, AUD m), 2013-2014
Table 8.9 Avita Medical: Regenerative Medicine Clinical Trials, 2015
Table 8.10 AxoGen: Historical Sales ($m) and Net Loss ($m), 2010-2013
Table 8.11 AxoGen: Regenerative Medicine Clinical Trials, 2015
Table 8.12 Medipost: Historical Sales ($m, mil.KRW) and Net Income ($m, mil.KRW), 2011-2013
Table 8.13 Medipost: Regenerative Medicine Clinical Trials, 2015
Table 8.14 Mesoblast: Historical Sales ($m, AUD m), 2011-2014
Table 8.15 Mesoblast: Regenerative Medicine Clinical Trials, 2015
Table 8.16 NuVasive: Historical Sales ($m) and Net Income (Profits and Losses) ($m), 2009-2013
Table 8.17 NuVasive: Regenerative Medicine Clinical Trials, 2015
Table 8.18 Ocata Therapeutics: Historical Sales ($thousand) and Gross Income ($thousand), 2009-2013
Table 8.19 Ocata Therapeutic: Regenerative Medicine Clinical Trials, 2015
Table 8.20 Organogenesis: Regenerative Medicine Clinical Trials, 2015
Table 8.21 Osiris Therapeutics: Revenue ($m) and Net Income ($m), 2010-2013
Table 8.22 Osiris Therapeutics: Regenerative Medicine Clinical Trials, 2015
Table 8.23 Pharmicell: Historical Sales ($m, mil.KRW) and Net Income ($m, mil.KRW), 2011-2013
Table 8.24 Regenerys: Regenerative Medicine Clinical Trials, 2015
Table 8.25 Shire: Revenue ($m) and Net Income ($m), 2010-2013
Table 8.26 Shire: Regenerative Medicine Clinical Trials, 2015
Table 8.27 TiGenix: Historical Sales ($m, mEuros) and Net Income ($m, mEuros), 2011-2013
Table 8.28 TiGenix: Regenerative Medicine Clinical Trials, 2015
Table 8.29 UniQure: Regenerative Medicine Clinical Trials, 2015
Table 9.1 SWOT Analysis of the Global Translational Regenerative Medicine Market, 2015-2025
Table 11.1 Global Translational Regenerative Medicine: Market Forecast ($m, CAGR%), 2013, 2017, 2021, 2025
Table 11.2 Global Translational Regenerative Medicine Market: Revenue ($m) and Market Shares (%) by Sector, 2013
Table 11.3 Global Translational Regenerative Medicine Market: Revenue ($m) and Market Shares (%) by Region, 2013
Table 11.4 Global Translational Regenerative Medicine: Market Forecast ($m) by Sector, 2013, 2017, 2021, 2025
Table 11.5 Global Translational Regenerative Medicine Market: Products In Late Stage Development, 2015

List of Figures
Figure 1.1 Global Translational Regenerative Medicine Market: Submarkets, 2015
Figure 1.2 US Translational Regenerative Medicine Market: Market Forecast ($m, AGR%), 2013-2025 (Altered Data)
Figure 2.1 Timeline of Stem Cell Research, 1900-2014
Figure 2.2 Examples Of FDA-Approved Tissue Engineering Products, 2015
Figure 2.3 Brief History of Tissue Engineering, 1900-2014
Figure 2.4 Brief History of Gene Therapy, 1970-2014
Figure 3.1 The Global Translational Regenerative Medicine Market: Revenue ($m) by Sector, 2013 and 2014
Figure 3.2 The Global Translational Regenerative Medicine Market: Market Forecast ($m, AGR%), 2013-2025
Figure 3.3 The Global Translational Regenerative Medicine Market Forecast: CAGR (%) by Sector, 2013-2019
Figure 3.4 The Global Translational Regenerative Medicine Market Forecast: CAGR (%) by Sector, 2019-2025
Figure 3.5 The Global Translational Regenerative Medicine Market Forecast: CAGR (%) by Sector, 2013-2025
Figure 3.6 The Global Translational Regenerative Medicine Market: Revenue ($m) by Sector, 2013, 2019, 2025
Figure 3.7 The Global Translational Regenerative Medicine Market: Market Share (%) by Sector, 2013
Figure 3.8 The Global Translational Regenerative Medicine Market: Market Share (%) by Sector, 2019
Figure 3.9 The Global Translational Regenerative Medicine Market: Market Share (%) by Sector, 2025
Figure 4.1 Global Stem Cell Therapies: Market Forecast ($m, AGR%), 2013-2025
Figure 4.2 Osteocel Plus: Sales Forecast ($m, AGR%), 2013-2025
Figure 4.3 Trinity ELITE: Sales Forecast ($m, AGR%), 2013-2025
Figure 4.4 Prochymal: Sales Forecast ($m, AGR%), 2013-2025
Figure 5.1 Global Tissue Engineering Therapies: Market Forecast ($m, AGR%), 2013-2025
Figure 5.2 Apligraf: Sales Forecast ($m, AGR%), 2013-2025
Figure 5.3 Dermagraft: Sales Forecast ($m, AGR%), 2013-2025
Figure 5.4 ReCell: Sales Forecast ($m, AGR%), 2013-2025
Figure 6.1 Global Gene Therapies: Market Forecast ($m, AGR%), 2013-2025
Figure 6.2 Neovasculgen: Sales Forecast ($m, AGR%), 2013-2025
Figure 6.3 Glybera: Sales Forecast ($m, AGR%), 2013-2025
Figure 6.4 Talimogene Laherparepvec (T-Vec): Sales Forecast ($m, AGR%), 2013-2025
Figure 7.1 The Global Translational Regenerative Medicine Market: Market Size ($m) by Region, 2013 and 2014
Figure 7.2 Asia-Pacific, Europe, US, and ‘Rest of the World’ Translational Regenerative Medicine Market: Market Forecast ($m), 2013-2025
Figure 7.3 Global Translational Regenerative Medicine Market: CAGR (%) by Region, 2013-2019
Figure 7.4 Global Translational Regenerative Medicine Market: CAGR (%) by Region, 2019-2025
Figure 7.5 Global Translational Regenerative Medicine Market: CAGR (%) by Region, 2013-2025
Figure 7.6 Global Translational Regenerative Medicine Market: Market Share (%) by Region, 2013
Figure 7.7 Global Translational Regenerative Medicine Market: Market Share (%) by Region, 2019
Figure 7.8 Global Translational Regenerative Medicine Market: Market Share (%) by Region, 2025
Figure 7.9 US Translational Regenerative Medicine Market: Market Forecast ($m, AGR%), 2013-2025
Figure 7.10 European Translational Regenerative Medicine Market: Market Forecast ($m, AGR%), 2013-2025
Figure 7.11 Asia-Pacific Translational Regenerative Medicine Market: Market Forecast ($m, AGR%), 2013-2025
Figure 7.12 Rest of the World Translational Regenerative Medicine Market: Market Forecast ($m, AGR%), 2013-2025
Figure 8.1 Aastrom: Historical Sales ($Thousand, AGR%), 2011-2013
Figure 8.2 Alphatec Spine: Historical Sales ($m) and Operating Loss ($m), 2009-2013
Figure 8.3 Athersys: Historical Sales ($m) 2010-2013
Figure 8.4 Avita Medical: Historical Sales ($m, AUD m) and Net Loss ($m, AUD m), 2013-2014
Figure 8.5 AxoGen: Historical Sales ($m) and Net Loss ($m), 2010-2013
Figure 8.6 Medipost: Historical Sales ($m, mil.KRW) and Net Income ($m, mil.KRW), 2011-2013
Figure 8.7 Mesoblast: Historical Sales ($m, AUD m), 2011-2014
Figure 8.8 NuVasive: Historical Sales and Net Income (Profits and Losses) ($m), 2009-2013
Figure 8.9 Ocata Therapeutics: Historical Sales ($thousand) and Gross Income ($thousand), 2009-2013
Figure 8.10 Osiris Therapeutics: Revenue ($m) and Net Income ($m), 2010-2013
Figure 8.11 Pharmicell: Historical Sales (mil.KRW) and Net Income (mil.KRW), 2011-2013
Figure 8.12 Shire: Revenue ($m) and Net Income ($m), 2010-2013
Figure 8.13 TiGenix: Historical Sales ($m, mEuros) and Net Income ($m, mEuros), 2011-2013
Figure 9.1 Porter’s Five Force Analysis of the Translational Regenerative Medicine Market, 2015
Figure 11.1 Global Translational Regenerative Medicine: Market Forecast ($m), 2013, 2017, 2021, 2025
Figure 11.2 Global Translational Regenerative Medicine Market: Revenue ($m) by Sector, 2013
Figure 11.3 Global Translational Regenerative Medicine: Market Forecast ($m) by Sector, 2013-202

【掲載企業】

Aastrom Biosciences
Advanced BioHealing
Advanced Cell Technology
Advanced Tissue Sciences
Advantagene
AlloSource
AlphaTec Spine
Amedica
Amgen
Amorcyte
Amorepacific Group
AnGes MG
Angioblast Systems
Anika Therapeutics
Anterogen
Arcarios B.V
Ark Therapeutics
Athersys Inc
Avita Medical
AxoGen
Baxter
Beike Biotechnology
Benda Pharmaceutical
BioD
Bioheart
BioMed Realty Trust, Inc
BioSante Pharmaceuticals
BioTime
BioTissue AG
BioVex Inc
Blackstone Medical
BrainStorm Cell Therapeutics
California Stem Cell Inc
Capricor
Cardio3BioSciences
Celgene
Cell Targeting
CellCo Tec
Cellerant Therapeutics
Cephalon
Ceregene
CHA Biotech
Chiesi Farmaceutici
Cipla
Co.don AG
Cold Genesys
Cook Biotech Inc
Cytomedix
Cytori Therapeutics
Daiichi Sankyo
DePuy Mitek (Johnson & Johnson)
FibroCell
Gamida Cell Ltd
Genzyme Corporation (Sanofi)
Histogenics
Humacyte
Human Stem Cell Institute
Insulete Inc
Interxon Corporation
ISTO Technologies
Janssen Biotech Inc
Japan Tissue Engineering Co
JCR Pharmaceuticals
Johnson & Johnson
Kinetic Concept Inc
LecTec Corporation
Lincoln Park Capital
Lonza
MacroCure
Medipost
Medtronic
Mesoblast
Mitsubishi Tanabe
Myriad Genetics
Neostem
Neuralstem
Nippon Zoki Pharmaceuticals
NuVasive
Ocata Therapeutics
OncoCyte
Organovo
Orphan Biovitrum AB (Sobi)
Orthofix
Osiris Therapeutics
Oxford BioMedica
Parcell Laboratories
Pfizer
Pharmicell
Regenerys
Reliance Life Sciences
ReNeuron
RTI Surgical
Rusnano Corporation
Sangamo Biosciences
Sanofi
Shanghai Sunway Biotech
Shenzhen Sibiono GeneTech
Shire
Singapore General Hospital
Skye Orthobiologics
Smith & Nephew
Sobi Partners
Spark Therapeutics
StemCells
Stempeutics Research
Stratatech Corporation
TCA Cellular Therapy
Tengion Inc
Teva Pharmaceuticals
TiGenix
UniQure
Viacyte Inc
Vital Therapies
WKD Holding Oy
Xcellerex
Xenetic Biosciences
Zimmer

Organisations Mentioned In The Report
Arthritis Research UK
Associazione Infermieristica per lo Studio delle Lesioni Cutanee (AISLeC) [China]
Australian Regenerative Medicine Institute
Australian Sports Anti-Doping Authority (ASADA)
Biomedical Advanced Research and Development Authority (BARDA)
British Heart Foundation [UK]
California Institute of Regenerative Medicine (CIRM)
Cambridge Stem Cell Biology Institute [UK]
Case Western Reserve University
Catalan Institution for Research and Advanced Studies
Center for Biologics Evaluation and Research (CBER) [US]
CHA General Hospital [Korea]
Cryocenter Saint Petersburg
Drugs Controller General of India (DCGI)
European Group for Blood and Marrow Transplantation (EBMT)
European Medicines Agency
Food and Drugs Agency (FDA) [US]
Haute Autorité de santé [France]
Heriot-Watt University
Human Fertilisation and Embryology Authority (HFEA)
Institute of Biomedical Research and Innovation Hospital [Japan]
International Society for Stem Cell Research (ISSCR)
Karolinska Institute [Sweden]
Massachusetts General Hospital (MGH)
Mayo Clinic [US]
Medical Research Council [UK]
Ministry of Food and Drug Safety, MFDS) [Korea]
Ministry of Health, Labour and Welfare (MHLW) [Japan]
Ministry of Science and Technology [China]
Moorfields Eye Hospital
National Tissue Engineering Center (NTEC) [China]
New York Blood Center
Riken Center for Developmental Biology
RUSH University Medical Center [US]
Russian Ministry of Healthcare and Social Development
Saudi Food and Drug Authority [Saudi Arabia]
Scottish Centre for Regenerative Medicine
Sotex Pharm Firm LLC
St. Jude’s Children Research Hospital
State Food and Drug Administration (SFDA) [China]
SUNY Upstate Medical University
The Genetico Center [Russia]
The StemGen Organisation
Therapeutics Goods Administration (TGA) [Australia]
UH San Diego Sanford Stem Cell Clinical Center
UK Medicines and Healthcare Products Regulatory Agency (MHRA)
Universitat Autònoma de Barcelona [Spain]
University College London
University of Edinburgh MRC Centre for Regenerative Medicine [UK]
University of Massachusetts (UMass) Memorial Hospital
University of Modena Centre for Regenerative Medicine [Italy]
University of Wisconsin
Wake Forest Institute
Weizmann Institute of Science [Israel]
Wellcome Trust
World Health Organization
Yale School of Medicine

【レポートのキーワード】

トランスレーショナル再生医療、再生医学、幹細胞治療、ティッシュ・エンジニアリング治療、遺伝子治療、用途

★調査レポート[トランスレーショナル再生医療の世界市場:幹細胞治療、ティッシュ・エンジニアリング治療、遺伝子治療] ( Translational Regenerative Medicine: Market Prospects 2015-2025 / VGAIN5020411) 販売に関する免責事項
[トランスレーショナル再生医療の世界市場:幹細胞治療、ティッシュ・エンジニアリング治療、遺伝子治療] ( Translational Regenerative Medicine: Market Prospects 2015-2025 / VGAIN5020411) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆